Endometrial / Uterine Cancer (Nutritional Support)
Most common gynecologic malignancy driven by estrogen excess and obesity requiring estrogen metabolism optimization, insulin sensitization, and targeted immunotherapy support
Overview
Endometrial cancer is the most common gynecologic malignancy in the US (~67,000 new cases/year) and the sixth most common cancer in women globally. Type I endometrial cancer (endometrioid, ~80%) is estrogen-driven, associated with obesity, diabetes, PCOS, and Lynch syndrome; generally good prognosis. Type II (serous, clear cell, carcinosarcoma, ~20%) is estrogen-independent, more aggressive, and carries worse prognosis. Five-year survival: ~95% for stage I, ~17% for stage IV. Treatments: total hysterectomy + bilateral salpingo-oophorectomy (BSO) with sentinel lymph node biopsy, pelvic radiation (EBRT, vaginal brachytherapy), chemotherapy (carboplatin + paclitaxel — standard), pembrolizumab + lenvatinib (KEYNOTE-146/Study 111 — FDA approved 2019 for advanced endometrial cancer regardless of MSI status), pembrolizumab monotherapy for MSI-H/dMMR tumors, dostarlimab (anti-PD-1, FDA approved 2021 for dMMR endometrial cancer). 2025–2026 advances: RUBY trial final OS (2024) — dostarlimab + carboplatin/paclitaxel: OS 44.6 vs 28.2 months in advanced endometrial cancer (HR 0.64); dostarlimab now FDA approved first-line for dMMR/MSI-H advanced endometrial cancer; ENGOT-EN6/GOG-3031 (NRG-GY018) — pembrolizumab + carboplatin/paclitaxel: PFS benefit confirmed (HR 0.30 for dMMR, HR 0.54 for pMMR); both dostarlimab and pembrolizumab now standard first-line with chemotherapy; fam-trastuzumab deruxtecan (T-DXd/Enhertu) — DESTINY-PanTumor02 (2024): 57.5% ORR in HER2+ serous endometrial cancer; FDA approved 2024 for HER2+ endometrial cancer; trastuzumab + carboplatin/paclitaxel for HER2+ serous endometrial cancer (STATEC/GOG-3018: improved PFS); selinexor (XPO1 inhibitor) for TP53-mutant endometrial cancer (SIENDO trial: improved PFS in TP53-mutant disease); comprehensive molecular profiling (POLE, MMR/MSI, p53, NSMP) now standard — TCGA/ProMisE classification guides adjuvant therapy decisions; lenvatinib + pembrolizumab OS data (KEYNOTE-775 2024 update: 18.3 vs 11.4 months). Nutritional rationale: obesity is the strongest modifiable risk factor (obese women have 3–4x increased risk); hyperinsulinemia and IGF-1 drive endometrial proliferation; estrogen produced in adipose tissue drives Type I endometrial cancer; weight loss of 5–10% significantly reduces recurrence risk; DIM and flaxseed lignans support estrogen metabolism.
Evidence highlight: RUBY trial final OS (2024): dostarlimab + carboplatin/paclitaxel OS 44.6 vs 28.2 months (HR 0.64) in advanced endometrial cancer (Mirza et al., 2024). NRG-GY018/ENGOT-EN6: pembrolizumab + carboplatin/paclitaxel PFS HR 0.30 (dMMR) and HR 0.54 (pMMR) (Eskander et al., 2023). DESTINY-PanTumor02 (2024): T-DXd 57.5% ORR in HER2+ serous endometrial cancer. Selinexor FDA approved 2023 for endometrial cancer — SIENDO trial: PFS HR 0.55 in TP53-mutant disease. KEYNOTE-775 (2024 update): lenvatinib + pembrolizumab OS 18.3 vs 11.4 months second-line. Obesity increases endometrial cancer risk 3–4x; bariatric surgery reduces risk by 70% (Mackintosh et al., 2013). DIM promotes 2-hydroxyestrone over 16-hydroxyestrone in clinical studies (Bradlow et al., 1994).
Core Nutrition Principles
- 1Obesity is the strongest modifiable risk factor — adipose tissue produces estrogen via aromatase; weight loss of 5–10% significantly reduces recurrence risk and improves survival
- 2Insulin resistance and hyperinsulinemia drive endometrial proliferation via IGF-1 — low-glycemic, high-fiber diet and berberine/metformin are critical interventions
- 3Estrogen metabolism optimization is essential for Type I endometrial cancer — DIM, flaxseed lignans, cruciferous vegetables, and fiber reduce estrogen and promote 2-hydroxyestrone over 16-hydroxyestrone
- 4Mediterranean diet reduces endometrial cancer risk by 30–40% in prospective studies — anti-inflammatory, low-glycemic, high-fiber pattern
- 5Vitamin D deficiency is strongly associated with endometrial cancer risk and worse prognosis — supplementation supports immune surveillance and immunotherapy response
- 6Omega-3 EPA/DHA reduce prostaglandin E2 and aromatase activity — reduce estrogen production in adipose tissue and tumor microenvironment
- 7Fiber (25–35g/day) reduces circulating estrogen by promoting fecal estrogen excretion and supporting healthy estrobolome (gut bacteria that metabolize estrogens)
- 8Alcohol increases circulating estrogen and endometrial cancer risk — complete avoidance recommended
Priority Foods
- Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, kale) — DIM and sulforaphane; promote 2-hydroxyestrone over 16-hydroxyestrone; anti-tumor; eat daily
- Ground flaxseed (2 tablespoons/day) — lignans; reduce estrogen; anti-tumor; fiber for estrogen excretion; add to smoothies, oatmeal, or yogurt
- Wild-caught fatty fish (salmon, sardines, mackerel) — omega-3 EPA/DHA; reduce aromatase activity; anti-inflammatory; reduce prostaglandin E2
- Legumes (lentils, chickpeas, black beans) — fiber; low-glycemic protein; reduce insulin resistance; phytoestrogens (weak, protective in endometrial cancer)
- Berries (blueberries, raspberries, strawberries) — antioxidants; low-glycemic; anti-inflammatory; ellagic acid anti-tumor
- Leafy greens (spinach, arugula, Swiss chard) — folate; magnesium; antioxidants; fiber; low-calorie for weight management
- Whole grains (oats, quinoa, barley) — fiber; low-glycemic; B vitamins; reduce insulin resistance
- Turmeric with black pepper — curcumin; inhibits aromatase; anti-tumor; NF-kB inhibition; anti-inflammatory
- Green tea (3–5 cups/day) — EGCG; inhibits aromatase; anti-proliferative in endometrial cancer cell lines; antioxidant
- Pomegranate — ellagic acid; inhibits aromatase; anti-tumor; anti-inflammatory
- Olive oil — oleocanthal; anti-inflammatory; monounsaturated fats; Mediterranean diet cornerstone
Core Supplements
- DIM (diindolylmethane) — 200–400mg daily; promotes 2-hydroxyestrone over 16-hydroxyestrone; anti-tumor in endometrial cancer cell lines; most important supplement for Type I endometrial cancer
- Vitamin D3 — 5,000–10,000 IU daily with K2 (200mcg MK-7); deficiency strongly associated with endometrial cancer risk; immune support; immunotherapy response; target 60–80 ng/mL
- Omega-3 EPA/DHA — 3–4g daily; reduce aromatase activity; anti-inflammatory; reduce prostaglandin E2; anti-cachexia
- Berberine — 500mg twice daily with meals; insulin sensitizer (comparable to metformin); reduces IGF-1; anti-tumor in endometrial cancer cell lines; activates AMPK; max 1,500mg/day
- Flaxseed lignans (secoisolariciresinol diglucoside) — 50–100mg daily; reduce estrogen; anti-tumor; fiber support; use in addition to ground flaxseed
- Magnesium glycinate — 400–600mg daily; insulin sensitivity; reduces inflammation; sleep; muscle function post-surgery
- Curcumin (phytosome) — 500–1,000mg twice daily; inhibits aromatase; NF-kB inhibition; anti-tumor; anti-inflammatory; reduces chemotherapy toxicity
- Green tea extract (EGCG) — 400–800mg daily standardized to 45% EGCG; inhibits aromatase; anti-proliferative; antioxidant
- Probiotics (50 billion CFU) — estrobolome support; healthy gut bacteria metabolize estrogens properly; reduce circulating estrogen; Lactobacillus acidophilus + Bifidobacterium longum
- Melatonin — 10–20mg at bedtime; anti-tumor; inhibits aromatase; antioxidant; improves sleep post-surgery; discuss with oncologist
- Selenium (selenomethionine) — 200mcg daily; antioxidant; immune support; may reduce chemotherapy toxicity
- CoQ10 (ubiquinol) — 200–400mg daily; reduces carboplatin/paclitaxel cardiotoxicity; mitochondrial support; antioxidant
Treatment Protocols
- Total hysterectomy + bilateral salpingo-oophorectomy (BSO) — standard surgical treatment; minimally invasive (laparoscopic or robotic) preferred for most cases; sentinel lymph node biopsy for staging
- Vaginal brachytherapy — standard adjuvant radiation for intermediate-risk stage I endometrial cancer; reduces vaginal recurrence; fewer side effects than EBRT
- External beam radiation therapy (EBRT) — for high-risk or node-positive disease; pelvic EBRT ± para-aortic fields
- Carboplatin + paclitaxel — standard first-line chemotherapy for advanced or recurrent endometrial cancer; 6 cycles; well-tolerated
- Pembrolizumab + lenvatinib (KEYNOTE-146) — FDA approved 2019 for advanced endometrial cancer regardless of MSI status; 38% ORR; 7.4-month median PFS; second-line standard
- Dostarlimab (Jemperli) — anti-PD-1; FDA approved 2021 for dMMR/MSI-H recurrent endometrial cancer; 42% ORR; RUBY trial: dostarlimab + carboplatin/paclitaxel improved PFS and OS (2023)
- Pembrolizumab monotherapy — for MSI-H/dMMR endometrial cancer; 57% ORR; KEYNOTE-158
- Carboplatin + paclitaxel + pembrolizumab or dostarlimab — emerging first-line standard for advanced endometrial cancer based on RUBY and ENGOT-EN6 trials (2023–2024)
- Trastuzumab + carboplatin/paclitaxel — for HER2+ serous endometrial cancer (~30% of serous type); STATEC trial showing benefit
- Fam-trastuzumab deruxtecan (T-DXd) — ADC for HER2+ endometrial cancer; DESTINY-PanTumor02 trial showing activity; investigational for endometrial cancer
- Progestin therapy (medroxyprogesterone acetate, levonorgestrel IUD) — fertility-sparing option for young women with grade 1 stage IA endometrial cancer; 50–75% complete response rate
- Weight management — 5–10% weight loss reduces recurrence risk; bariatric surgery associated with 70% reduced endometrial cancer risk in morbidly obese women
- Lynch syndrome testing — universal MMR/MSI testing of all endometrial cancers; Lynch syndrome present in 3–5%; colonoscopy surveillance required
- RUBY trial final OS (2024) — dostarlimab + carboplatin/paclitaxel: OS 44.6 vs 28.2 months (HR 0.64) in advanced endometrial cancer; dostarlimab now FDA approved first-line for dMMR/MSI-H advanced endometrial cancer
- NRG-GY018/ENGOT-EN6 — pembrolizumab + carboplatin/paclitaxel: PFS HR 0.30 (dMMR) and HR 0.54 (pMMR); pembrolizumab now standard first-line with chemotherapy for all advanced endometrial cancer
- Fam-trastuzumab deruxtecan (T-DXd/Enhertu) — DESTINY-PanTumor02 (2024): 57.5% ORR in HER2+ serous endometrial cancer; FDA approved 2024; HER2 testing now recommended for all serous endometrial cancers
- Selinexor (Xpovio) — XPO1 nuclear export inhibitor; SIENDO trial: improved PFS in TP53-mutant endometrial cancer (HR 0.55); oral once weekly; FDA approved for endometrial cancer 2023
- TCGA/ProMisE molecular classification — POLE-mutant (best prognosis), MMR-deficient (immunotherapy benefit), p53-mutant (worst prognosis, HER2 testing), NSMP (intermediate); now standard for all endometrial cancers to guide adjuvant therapy
- KEYNOTE-775 (2024 update) — lenvatinib + pembrolizumab OS 18.3 vs 11.4 months in previously treated advanced endometrial cancer; confirms second-line standard
- Oncology dietitian — essential for weight management, insulin resistance, and estrogen metabolism optimization
Foods & Substances to Avoid
- Excess body weight and obesity — adipose tissue produces estrogen via aromatase; obesity is the strongest modifiable risk factor (3–4x increased risk); weight management is the most impactful intervention
- High-glycemic foods (white bread, sugary drinks, candy, white rice) — drive hyperinsulinemia and IGF-1; promote endometrial proliferation; most important dietary avoidance for Type I endometrial cancer
- Alcohol — increases circulating estrogen; associated with increased endometrial cancer risk; impairs immune function during immunotherapy
- Red and processed meats — pro-inflammatory; associated with increased endometrial cancer risk; promote insulin resistance
- Refined vegetable oils (corn, soybean, sunflower) — high omega-6; promote aromatase activity and prostaglandin E2; increase estrogen production
- Grapefruit — inhibits CYP3A4; significantly alters lenvatinib, pembrolizumab metabolism; avoid during targeted therapy
- High-dose estrogen supplements or phytoestrogen supplements — avoid in Type I estrogen-driven endometrial cancer; food-source phytoestrogens (soy foods, flaxseed) are safe and protective
- Processed foods and trans fats — promote inflammation and insulin resistance; worsen obesity-driven endometrial cancer risk
- St. John's Wort — CYP3A4 inducer; reduces lenvatinib efficacy
Get your personalized protocol
Take the full assessment to receive a protocol tailored to your specific symptoms and goals.
Start AssessmentKey Nutrients
Drug & Supplement Interactions
Some nutrients in this protocol may interact with medications. Always inform your prescriber of all supplements you take.
- •Warfarin (Coumadin) — vitamin K directly antagonizes warfarin; any change in intake requires INR monitoring
- •Other anticoagulants (rivaroxaban, apixaban) — consult prescriber before supplementing
- •Antibiotics — broad-spectrum antibiotics reduce gut bacteria that produce vitamin K2
- •Warfarin (Coumadin) — directly antagonizes anticoagulant effect; requires INR monitoring
- •Other anticoagulants — consult prescriber; even small changes in K2 intake affect INR
- •Retinoids (isotretinoin, tretinoin) — additive toxicity risk; do not combine
- •Warfarin — high-dose vitamin A may increase anticoagulant effect
- •Orlistat — reduces fat-soluble vitamin absorption including vitamin A
- •Cholestyramine — reduces vitamin A absorption
- •Levodopa — B6 reduces drug effectiveness; avoid unless combined with carbidopa
- •Phenytoin and phenobarbital — B6 may reduce drug levels
- •Statins — combination increases risk of myopathy; use with caution
- •Diabetes medications — high-dose niacin may impair glucose control
- •Blood pressure medications — additive vasodilatory effect
- •Metformin and diabetes medications — additive blood-glucose-lowering effect; risk of hypoglycemia
- •Blood thinners (warfarin) — may increase anticoagulant effect; monitor INR
- •Cyclosporine — berberine inhibits CYP3A4; may increase drug levels
- •Antibiotics — may reduce effectiveness of some antibiotics
- •Blood pressure medications — additive hypotensive effect
- •Doxorubicin (chemotherapy) — may increase drug levels
- •Thiazide diuretics — combined with high-dose vitamin D may cause hypercalcemia
- •Digoxin — hypercalcemia from excess vitamin D increases digoxin toxicity risk
- •Corticosteroids — long-term use depletes vitamin D; supplementation is recommended
- •Orlistat (weight loss drug) — reduces vitamin D absorption by up to 30%
- •Cholestyramine — reduces vitamin D absorption; separate by 4+ hours
- •Phenobarbital and phenytoin — accelerate vitamin D metabolism; may require higher doses
- •Blood thinners (warfarin, aspirin) — additive antiplatelet effect at doses >400 IU/day
- •Chemotherapy and radiation — high-dose vitamin E may reduce treatment effectiveness; consult oncologist
- •Statins — may reduce statin effectiveness at very high doses
- •Cyclosporine — may reduce drug levels
- •Niacin — high-dose combination may reduce HDL-raising effect of niacin
- •Warfarin — high doses (>1g/day) may reduce anticoagulant effect
- •Chemotherapy — high-dose IV vitamin C may interact with certain agents; consult oncologist
- •Iron supplements — significantly enhances iron absorption (beneficial in deficiency, caution in hemochromatosis)
- •Statins — very high doses may reduce statin effectiveness
- •Aluminum antacids — vitamin C increases aluminum absorption; avoid combination
- •Metformin — long-term use depletes B12; supplementation is recommended
- •PPIs and H2 blockers — reduce B12 absorption; supplementation recommended with long-term use
- •Chloramphenicol — may reduce B12 effectiveness
- •Blood thinners (warfarin, clopidogrel, aspirin) — additive antiplatelet effect; monitor INR at doses >2g/day
- •Blood pressure medications — additive hypotensive effect at high doses (>3g/day)
- •Cyclosporine — may reduce drug levels; monitor in transplant patients
- •Blood thinners — mild antiplatelet effect; monitor with anticoagulants
- •Oral medications — high fiber content may slow absorption; separate by 1–2 hours
- •Estrogen-sensitive medications — flaxseed lignans have weak estrogenic activity
- •Blood thinners (warfarin, aspirin, clopidogrel) — additive antiplatelet effect at high doses
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Chemotherapy drugs — may interact with certain agents; consult oncologist
- •Acid-reducing medications (PPIs, H2 blockers) — curcumin may reduce stomach acid
- •Iron — may reduce iron absorption
- •Blood thinners — mild antiplatelet effect
- •Iron — significantly reduces iron absorption; separate by 2+ hours
- •Bortezomib (chemotherapy) — EGCG may reduce drug effectiveness
- •Stimulants — green tea EGCG contains caffeine; additive stimulant effect
- •Blood thinners (warfarin) — may reduce anticoagulant effect at high doses
- •Iron — reduces iron absorption; separate by 2+ hours
- •Stimulants and caffeine — additive stimulant effect
- •Bortezomib (chemotherapy) — may reduce drug effectiveness
- •Adenosine — caffeine in green tea blocks adenosine receptors
- •Antibiotics (tetracyclines, fluoroquinolones) — magnesium reduces absorption; separate by 2+ hours
- •Bisphosphonates (alendronate) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Diuretics — thiazide diuretics increase magnesium excretion; loop diuretics may deplete magnesium
- •Digoxin — magnesium deficiency increases digoxin toxicity risk; supplementation may be protective
- •Muscle relaxants — additive effect; may increase sedation
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Bisphosphonates — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics (tetracyclines, fluoroquinolones) — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Antibiotics — reduces absorption; separate by 2+ hours
- •Diabetes medications — may enhance blood-glucose-lowering effect
- •Chemotherapy (cisplatin) — may reduce drug effectiveness; consult oncologist
- •Anticoagulants — high doses may have mild antiplatelet effect
- •Statins — may interact with statin metabolism at high doses
This list covers common interactions and is not exhaustive. Consult a pharmacist or physician before combining supplements with prescription medications.
Related Conditions
This protocol is for informational purposes only. Consult a qualified healthcare provider before making dietary or supplement changes.